About Sherif Elsaraj
Dr. Elsaraj was raised in Ottawa where he attended JS Wordsworth Secondary School followed by a B.Sc. Honours in Biochemistry from Carleton University (2004). He then completed his M.Sc. in Oral Biology (2006) and Doctor of Medicine in Dentistry (2010), both at the University of Manitoba, and a Ph.D. in Craniofacial Pain and Health Sciences from McGill University (2022). Dr. Elsaraj is also a Fellow of the Pierre Fauchard Academy (2024), and a Fellow of the American Academy of Craniofacial Pain (2024).
Dr. Elsaraj is an active member of the Canadian Dental Association (CDA), Manitoba Dental Association (MDA), Ontario Dental Association (ODA), and the Order des Dentistes du Québec. He is a Faculty Lecturer at the University of Ottawa (Faculty of Medicine) and McGill University (Department of Dentistry at the Jewish General Hospital), where he lectures and supervises graduate residents in the General Residency Program for Orofacial Pain (OFP) and Temporomandibular Disorders (TMD) Clinic.
Dr. Elsaraj is currently the Vice President and Chair of the Continuing Education Committee of the Ottawa Dental Society (ODS). He serves on the Executive Council for both the ODS and ODA, is a member of the Continuing Education Advisory Committee (ODA), and acts as an Economics Committee Advisor (ODA). Additionally, he is the Political Contact Dentist for Nepean West (ODS), Chair of the Dental Emergency Service (ODS), and a member of the Long-Term Planning Committee (ODS).
He also serves as a TMD consultant for the Oral Health Group and Hull Hospital (CISSSO), a Dental Advisor for the Canadian Academy of Clinical Sleep Disorders Disciplines (CACSDD), and is a member of the Scientific Committee of the American Academy of Dental Sleep Medicine (AADSM).
Dr. Elsaraj engages in research at McGill University Jewish General Hospital Campus and the Centre de recherche en médecine psychosociale du CISSS de l'Outaouais (CISSSO). His focus includes identifying biomarkers for early detection of sleep apnea, exploring risk factors linked to the transition from acute to chronic pain, and evaluating the effectiveness of MAD therapy to mitigate the severity of COMISA.
